首页> 外文OA文献 >Combined Therapy with Renin-Angiotensin System and Calcium Channel Blockers in Type 2 Diabetic Hypertensive Patients with Proteinuria: Effects on Soluble TWEAK, PTX3, and Flow-Mediated Dilation
【2h】

Combined Therapy with Renin-Angiotensin System and Calcium Channel Blockers in Type 2 Diabetic Hypertensive Patients with Proteinuria: Effects on Soluble TWEAK, PTX3, and Flow-Mediated Dilation

机译:2型糖尿病合并蛋白尿的糖尿病患者联合肾素-血管紧张素系统和钙通道阻滞剂的联合治疗:对可溶性TWEAK,PTX3和血流介导的扩张的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background and objectives: Soluble TNF-like weak inducer of apoptosis (sTWEAK) and long pentraxin-3 (PTX3) concentrations have been associated with endothelial function in patients with chronic kidney disease (CKD). This study tested the hypothesis that the improvement in endothelial function after initiation of angiotensin II receptor blocker (valsartan), calcium channel blocker (amlodipine) therapy, or a combination of both is directly linked to the normalization of sTWEAK and PTX3.
机译:背景与目的:慢性肾脏病(CKD)患者的内皮功能与可溶性TNF样弱凋亡诱导剂(sTWEAK)和长的pentraxin-3(PTX3)浓度有关。这项研究检验了以下假设,即启动血管紧张素II受体阻滞剂(缬沙坦),钙通道阻滞剂(氨氯地平)或两者结合后,内皮功能的改善与sTWEAK和PTX3的正常化直接相关。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号